Redeye provides an initial take following the release of Optomed’s Q3 2025 report. The report was broadly in line with our fairly high expectations, with particularly strong momentum in the Devices segment. Overall, we view the report positively and anticipate an upward share price reaction today. A more detailed research update will follow shortly, and we do not foresee any major adjustments to our fair value range.
LÄS MER
